IRIS - Res&Arch Institutional Research Information System - Research & Archive

SPORTOLETTI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.695
AS - Asia 4.003
EU - Europa 3.331
SA - Sud America 646
AF - Africa 109
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 12.794
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.551
SG - Singapore 1.870
IT - Italia 1.034
IE - Irlanda 579
CN - Cina 572
BR - Brasile 496
HK - Hong Kong 470
VN - Vietnam 404
RU - Federazione Russa 400
DE - Germania 240
FR - Francia 198
FI - Finlandia 170
SE - Svezia 138
KR - Corea 132
UA - Ucraina 130
GB - Regno Unito 121
IN - India 110
BD - Bangladesh 105
CA - Canada 66
MX - Messico 57
AR - Argentina 54
RO - Romania 53
TR - Turchia 50
AT - Austria 44
NL - Olanda 44
IQ - Iraq 35
UZ - Uzbekistan 35
BE - Belgio 33
PL - Polonia 32
PK - Pakistan 30
ZA - Sudafrica 28
JP - Giappone 25
CZ - Repubblica Ceca 22
ES - Italia 22
ID - Indonesia 22
PH - Filippine 22
CO - Colombia 20
CH - Svizzera 18
EC - Ecuador 18
LT - Lituania 17
SA - Arabia Saudita 17
VE - Venezuela 16
EG - Egitto 15
PE - Perù 14
JO - Giordania 12
MA - Marocco 11
CL - Cile 9
ET - Etiopia 9
AZ - Azerbaigian 8
KE - Kenya 8
MY - Malesia 8
CI - Costa d'Avorio 7
IL - Israele 7
IR - Iran 7
KZ - Kazakistan 7
LB - Libano 7
NP - Nepal 7
PY - Paraguay 7
TH - Thailandia 7
TN - Tunisia 7
UY - Uruguay 7
AL - Albania 6
PT - Portogallo 6
BO - Bolivia 5
KG - Kirghizistan 5
PS - Palestinian Territory 5
CR - Costa Rica 4
JM - Giamaica 4
PA - Panama 4
SC - Seychelles 4
AO - Angola 3
AU - Australia 3
DO - Repubblica Dominicana 3
GE - Georgia 3
GR - Grecia 3
KW - Kuwait 3
NZ - Nuova Zelanda 3
QA - Qatar 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
DK - Danimarca 2
DZ - Algeria 2
EU - Europa 2
HR - Croazia 2
IM - Isola di Man 2
KH - Cambogia 2
LV - Lettonia 2
MK - Macedonia 2
NG - Nigeria 2
NI - Nicaragua 2
OM - Oman 2
SN - Senegal 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
UG - Uganda 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
Totale 12.772
Salva come PNG Salva come JPEG
Città #
Singapore 1.393
Chandler 594
Dublin 572
San Jose 550
Perugia 489
Hong Kong 470
San Mateo 384
Ashburn 319
Boardman 207
Santa Clara 182
Dong Ket 140
Altamura 131
Lauterbourg 131
Moscow 129
Seoul 129
Munich 117
Medford 108
Princeton 105
Beijing 103
Lawrence 101
Ho Chi Minh City 86
New York 84
Ann Arbor 81
Los Angeles 80
Hanoi 66
Wilmington 66
Andover 63
Helsinki 63
Jacksonville 59
Turku 56
Piscataway 49
The Dalles 49
São Paulo 45
Bucharest 44
Rome 36
Brussels 33
Council Bluffs 33
Houston 29
Des Moines 28
Brooklyn 27
Dallas 27
Frankfurt am Main 27
Dearborn 26
Nuremberg 25
Redmond 25
Tokyo 25
Foligno 23
Orem 23
Vienna 23
Mexico City 22
Shanghai 22
Tashkent 22
Warsaw 22
Amsterdam 21
Hefei 21
Belo Horizonte 20
London 20
Montreal 20
San Paolo di Civitate 20
Rio de Janeiro 19
Milan 18
Norwalk 18
Chennai 17
Redwood City 17
Toronto 17
Barnet 16
Assisi 15
Atlanta 15
Haiphong 15
San Francisco 15
Chicago 14
Izmir 14
Saint Petersburg 14
Stockholm 14
Baghdad 13
Denver 13
Johannesburg 13
Manchester 13
Phoenix 13
Ankara 12
Guangzhou 12
Menlo Park 12
Mumbai 12
Amman 11
Brno 11
Charlotte 11
Falkenstein 9
Istanbul 9
Paris 9
Poplar 9
Woodbridge 9
Changsha 8
Collazzone 8
Falls Church 8
Jakarta 8
Manila 8
Tianjin 8
Abidjan 7
Addis Ababa 7
Baku 7
Totale 8.363
Salva come PNG Salva come JPEG
Nome #
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia 181
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells 178
Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutation. 176
Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice 174
BCOR gene alterations in hematological diseases 167
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? 162
Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia 160
A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis 160
Notch1 modulates mesenchymal stem cells mediated regulatory T-cell induction 156
Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo. 154
ARSENIC TRIOXIDE AND ALL-TRANS-RETINOIC ACID TARGET NPM1 MUTANT ONCOPROTEIN LEVELS AND INDUCE APOPTOSIS IN NPM1-MUTATED AML CELLS 143
NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models 143
Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL 136
Mutant NPM1 Maintains the Leukemic State through HOX Expression 135
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia 132
NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. 131
GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations 131
Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita 130
NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the NOTCH1 and IGHV Mutational Status 129
Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. 128
Wnt/beta-Catenin Signaling Induces Integrin alpha 4 beta 1 in T Cells and Promotes a Progressive Neuroinflammatory Disease in Mice 127
NPM1 AND FLT3-ITD MUTATIONS SINERGISTICALLY INDUCE GATA1 EPIGENETIC SILENCING IN A AML MOUSE MODEL 126
NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications 126
Mesenchymal cells: a vehicle for gene therapy 125
GSK3β is a critical, druggable component of the network regulating the active NOTCH1 protein and cell viability in CLL 124
Clinical-Grade Expanded Regulatory T Cells Prevent Graft-versus-Host Disease While Allowing a Powerful T Cell Dependent Graft-versus-Leukemia Effect in Murine Models 123
The NOTCH1/CD39 axis: A Treg trip-switch for GvHD 120
Blockade of Oncogenic NOTCH1 With the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia 118
Human stromal cells engineered with interleukin-7 enhance the survival of naive T lymphocytes. 117
NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells. 117
IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation. 114
The radiosensitizer Silver nanoparticles effects are prevent to ion channel blocker DIDS in U251 human glioblastoma cell line. 113
Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice 111
CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity. 111
T regulatory cell separation for clinical application. 110
Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome 110
NPM1 AND FLT3-ITD MUTATIONS COOPERATE TO IMPAIR HEMATOPOIETIC STEM/PROGENITOR CELLS DIFFERENTIATION AND DEREGULATE GATA1 IN A MOUSE MODEL OF AML 109
Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin 109
A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia 109
Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients 109
BRAF mutations in hairy-cell leukemia. 108
A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. 108
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity 108
Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML 107
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML 107
Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35 107
Isolation and characterization of a new human T regulatory cell subset from peripheral blood CD4+ T lymphocyte 106
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. 106
A novel NOTCH1 PEST domain mutation in a case of Chronic Lymphocytic Leukemia 106
Interleukin-7-engineered mesenchymal cells: in vitro effects on naive T-cell population. 106
Richter's transformation in the heart 105
The glucocorticoid-induced TNF receptor family-related protein (GITR) is critical to the development of acute pancreatitis in mice 102
CURCUMIN EXHIBITS IN VITRO AND IN VIVO ANTI-LEUKEMIC ACTIVITY INTERFERING WITH THE NOTCH1 PATHWAY AND INDUCING ENDOPLASMIC RETICULUM STRESS IN CHRONIC LYMPHOCYTIC LEUKEMIA 101
Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL 101
IN VITRO AND IN VIVO ANTILEUKEMIC ACTIVITY OF BEPRIDIL IN CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH INHIBITION OF THE NOTCH1 PATHWAY 100
The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. 99
Synthesis and characterization of UiO-66 metal-organic frameworks nanoparticles and their evaluation as drug delivery carriers in U251 glioblastoma cells 97
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML 97
NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. 95
Functions of the native NPM1 protein and its leukemic mutant 93
BEPRIDIL IS A POTENT NOTCH1 INHIBITOR AND EFFICIENTLY INDUCES APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) CELLS in vitro AND in vivo 93
A curious novel combination of nucleophosmin (Npm1) gene mutations leading to aberrant cytoplasmic dislocation of npm1 in acute myeloid leukemia (aml) 93
Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia 93
A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells 91
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 91
A NOVEL MECHANISM FOR NOTCH1 ACTIVATIONIN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS: INVOLVEMENT OF NOTCH1 ENDOSOMAL TRAFFICKING AND ALTERATIONS IN RAB PROTEINS 90
Glucocorticoidi-Induced TNFR family Related gene (GITR) enhances dendritic cell activity 90
Mutational landscape of AML with normal cytogenetics: biological and clinical implications 90
A pro-inflammatory environment in bone marrow of Treg transplanted patients matches with graft-versus-leukemia effect 88
NOTCH and NF-κB interplay in chronic lymphocytic leukemia is independent of genetic lesion. 88
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 88
Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications 86
Interleukin 7-engineered stromal cells: a new approach for hastening naive T cell recruitment 85
Identification and Characterization of Novel Rare Nucleophosmin (NPM1) Gene Mutations in Acute Myeloid Leukemia (AML) By a Combinatorial Approach of Immunohistochemistry and Molecular Analyses 84
Therapeutic Targeting Potential of Novel Silver Nanoparticles Coated with Anti-CD20 Antibody against Chronic Lymphocytic Leukemia 83
Mesenchymal cells recruit and regulate T regulatory cells. 83
FLT3-targeted therapy restores GATA1 pathway function in NPM1/FLT3-ITD mutated acute myeloid leukaemia 81
Catalase prevents DNA damage and cationic current activation by silver nanoparticles in U251 human glioblastoma cell line 80
Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation. 80
NPM1-mutated acute myeloid leukemia: from bench to bedside 80
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 79
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 78
A DYSREGULATED, DRUGGABLE PP2A/AKT/GSK3 beta AXIS SUSTAINS NOTCH1 SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 77
Nanotechnology Advances in the Detection and Treatment of Lymphoid Malignancies 75
Uncommon lymphoplasmacytic lymphoma with IgA paraproteinemia: a challenging clinical diagnosis solved by MYD88 mutation analysis. 75
Venetoclax plus azacitidine as genetic-driven bridge-to-transplant therapy for IDH2-mutated acute myeloid leukaemia (AML) refractory to intensive chemotherapy: proof-of-concept case reports 73
Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia 73
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience 73
NOTCH1 Aberrant Activation Is a Common Nonmutational Early Event in Chronic Lymphocytic Leukemia Hematopoietic Stem-Cells 72
NOTCH-1 ACTIVATION AND SUBCLONAL MUTATION NEGATIVELY IMPACT ON CHRONIC LYMPHOCYTIC LEUKEMIA OUTCOMES 71
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 71
A scale of "bad" co-mutations in NPM1-driven AML 70
NOTCH1-mutated chronic lymphocytic leukemia displays high endoplasmic reticulum stress response with druggable potential 68
Recurrent primary plasmacytoma of the eyelid with rapid regional metastasis. 68
High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the GIMEMA phase II LLC1518 - 'Veritas' study 67
Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation. 67
Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein α activity: implications in myelodysplastic syndrome and acute myeloid leukemia. 67
Starry sky pattern predicts RAS pathway activation in NPM1‐mutated acute myeloid leukemia 66
The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein 65
The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model 65
Totale 10.550
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.224
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.224
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021150 0 0 0 0 0 0 0 0 0 0 0 150
2021/20221.312 48 376 9 44 26 9 18 226 30 138 210 178
2022/20231.946 111 371 18 183 140 195 11 85 708 8 81 35
2023/2024918 40 81 52 35 6 24 282 10 52 31 137 168
2024/20252.398 77 195 63 81 293 142 211 172 478 109 366 211
2025/20265.265 360 303 237 597 741 482 902 324 554 491 159 115
Totale 13.243